Skip to main content
SpringerLink
Log in

Breast cancer with HER 2 overexpressed. From laboratory to clinical practice

  • Conference paper
Cancer du sein

  • 243 Accesses

Conclusions

Breast carcinoma with HER2 amplification and overexpression represents a particular subset of tumors displaying a peculiar tumor progression and response to conventional and targeted therapy. The identification of HER2 is therefore mandatory since the diagnosis of the disease in order to offer to the patient the best clinical management.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001;37:S3–S8.

    Article  PubMed  CAS  Google Scholar 

  2. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptor, is a mediator of lateral signaling. EMBO J 1997;16:1647–55.

    Article  PubMed  CAS  Google Scholar 

  3. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ, Yarden Y. A hierarchinal network of interreceptor interactions determines signal transduction by neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996;16:5276–87.

    PubMed  CAS  Google Scholar 

  4. Threadgill DW, Dlugosz AA, Hansen LA, Tennenbaum T, Lichti U, Yee D, LaMantia C, Mourton T, Herrup K, Harris RC. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science 1995;269:230–4.

    PubMed  CAS  Google Scholar 

  5. Meyer D,. Birchmeier C. Multiple essential functions of neuregulin in development. Nature 1995;378:386–90.

    Article  PubMed  CAS  Google Scholar 

  6. Sibilia M, Steinbach JP, Stingl L, Aguzzi A, Wagner EF. A strain-independent postnatal neurodegeneration in mice lacking the EGF receptor. EMBO J 1998;17:719–31.

    Article  PubMed  CAS  Google Scholar 

  7. Gassmann M, Casagranda F, Orioli D, Simon H, Lai C, Klein R, Lemke G. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 1995;378:390–4.

    Article  PubMed  CAS  Google Scholar 

  8. Lee K-F, Simon H, Chen H, Bates B, Hung M-C, Hauser C. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 1995;378:394–8.

    Article  PubMed  CAS  Google Scholar 

  9. Pierce JH, Arnstein P, DiMarco E, Artrip J, Kraus MH, Lonardo F, Di Fiore PP, Aaronson SA. Oncogenic potential of erbB-2 in human mammary epithelial cells. Oncogene 1991;6:1189–94.

    PubMed  CAS  Google Scholar 

  10. Liu Y, El-Ashry D, Chen D, Ding IYF, Kern FG. MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo. Breast Cancer Res Treat 1995;34:97–117.

    Article  PubMed  CAS  Google Scholar 

  11. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SC, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707–12.

    PubMed  CAS  Google Scholar 

  12. Zhou BP,. Hung MC. Novel targets of Akt, p21(Cipl/WAF1), and MDM2. Semin Oncol 2002;29:62–70.

    PubMed  CAS  Google Scholar 

  13. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 1987;237:178–82.

    PubMed  Google Scholar 

  14. Muthuswamy SK, Li D, Lelievre S, Bissell MJ, Brugge JS. ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nat Cell Biol 2001;3:785–92.

    Article  PubMed  CAS  Google Scholar 

  15. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000;406:747–52.

    Article  PubMed  CAS  Google Scholar 

  16. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein LP, Borresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869–74.

    Article  PubMed  CAS  Google Scholar 

  17. Bocker W, Moll R, Poremba C, Holland R, Van Diest PJ, Dervan P, Burger H, Wai D, Ina DR, Brandt B, Herbst H, Schmidt A, Lerch MM, Buchwallow IB. Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept. Lab Invest 2002;82:737–46.

    PubMed  Google Scholar 

  18. Bertucci F, Borie N, Ginestier C, Groulet A, Charafe-Jauffret E, Adelaide J, Geneix J, Bachelart L, Finetti P, Koki A, Hermitte F, Hassoun J, Debono S, Viens P, Fert V, Jacquemier J, Birnbaum D. Identification and validation of an ERBB2 gene expression signature in breast cancers. Oncogene 2004;23:2564–75.

    Article  PubMed  CAS  Google Scholar 

  19. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de R M, Perou CM. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367–74.

    Article  PubMed  CAS  Google Scholar 

  20. Campiglio M, Somenzi G, Olgiati C, Beretta G, Balsari A, Zaffaroni N, Valagussa P, Ménard S. Role of proliferation in HER2 status predicted response to doxorubicin. Int J Cancer 2003;105:568–73.

    Article  PubMed  CAS  Google Scholar 

  21. Balsari A, Casalini P, Bufalino R, Berrino F, Ménard S. Role of hormonal risk factors in HER2-positive breast carcinomas. Br J Cancer 2003;88:1032–4.

    Article  PubMed  CAS  Google Scholar 

  22. Gancberg D, Jarvinen T, Di Leo A, Rouas G, Cardoso F, Paesmans M, Verhest A, Piccart MJ, Isola J, Larsimont D. Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of HER-2/NEU testing. Breast Cancer Res Treat 2002;74:113–20.

    Article  PubMed  CAS  Google Scholar 

  23. Rhodes A, Jasani B, Anderson E, Dodson AR, Balaton AJ. Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. Am J Clin Pathol 2002;118:408–17.

    Article  PubMed  CAS  Google Scholar 

  24. Paik S, Bryant J, Tan-Chiu E, Romond E, Hiller W, Park K, Brown A, Yothers G, Anderson S, Smith R, Wickerham DL, Wolmark N. Real-world performance of HER2 testing-national surgical adjuvant breast and bowel project experience. J Natl Cancer Inst 2002;94:852–4.

    PubMed  Google Scholar 

  25. Lal P, Salazar PA, Hudis CA, Ladanyi M, Chen B. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dualcolor and single-color scoring. Am J Clin Pathol 2004;121:631–6.

    Article  PubMed  Google Scholar 

  26. Cell Markers and Cytogenetics Committees College of American Pathologists. Clinical laboratory assays for HER-2/neu amplification and overexpression: quality assurance, standardization, and proficiency testing. Arch Pathol Lab Med 2002;126:803–8.

    Google Scholar 

  27. Roche PC, Suman VJ, Jenkins RB, Davidson NE, Martino S, Kaufman PA, Addo FK, Murphy B, Ingle JN, Perez EA. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 2002;94:855–7.

    PubMed  Google Scholar 

  28. Winston JS, Ramanaryanan J, Levine E. HER-2/neu evaluation in breast cancer are we there yet? Am J Clin Pathol 2004;121:S33–S49.

    PubMed  Google Scholar 

  29. Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, Beitsch P, Khan A, Euhus D, Osborne C, Frenkel E, Hoover S, Leitch M, Clifford E, Vitetta E, Morrison L, Herlyn D, Terstappen LW, Fleming T, Fehm T, Tucker T, Lane N, Wang J, Uhr J. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A 2004;101:9393–8.

    Article  PubMed  CAS  Google Scholar 

  30. Ménard S, Forti S, Castiglioni F, Agresti R, Balsari A. HER2 as a prognostic factor in breast cancer. Oncology 2001;61:67–72.

    Article  PubMed  Google Scholar 

  31. Masood S,. Bui MM. Prognostic and predictive value of HER2/neu oncogene in breast cancer. Microsc Res Tech 2002;59:102–8.

    Article  PubMed  CAS  Google Scholar 

  32. Ménard S, Tagliabue E, Campiglio M, Pupa SM. Role of HER2 gene overexpression in breast carcinoma. J Cell Physiol 2000;182:150–62.

    Article  PubMed  Google Scholar 

  33. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma YL, Hung G, Robinson RA, Harris C, El-Naggar A, Slamon DJ, Phillips RN, Ross JS, Wolman SR, Flom KJ. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997;15:2894–904.

    PubMed  CAS  Google Scholar 

  34. Cooke T, Reeves J, Lannigan A, Stanton P. The value of the human epidermal growth factor receptor-2 (HER2) as a prognostic marker. Eur J Cancer 2001;37:3–10.

    Article  PubMed  Google Scholar 

  35. Volpi A, De Paola F, Nanni O, Granato AM, Bajorko P, Becciolini A, Scarpi E, Riccobon A, Balzi M, Amadori D. Prognostic significance of biologic markers in node-negative breast cancer patients: a prospective study. Breast Cancer Res Treat 2000;63:181–92.

    Article  PubMed  CAS  Google Scholar 

  36. Ross JS, Muraca PJ, Jaffe D. Multivariate analysis of prognostic factors in lymph node negative breast cancer. Mod Pathol 1998;11:26a.

    Google Scholar 

  37. Ménard S, Balsari A, Casalini P, Tagliabue E, Campiglio M, Bufalino R, Cascinelli N. HER2-positive breast carcinomas as a particular subset with peculiar clinical behaviors. Clin Cancer Res 2002;8:520–5.

    PubMed  Google Scholar 

  38. Van’T Veer LJ, Dai H, Van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530–6.

    Article  Google Scholar 

  39. Murthy SM, Goldschmidt RA, Rao LN, Ammirati M, Buchmann T, Scanlon EF. The influence of surgical trauma on experimental metastasis. Cancer 1989;64:2035–44.

    PubMed  CAS  Google Scholar 

  40. Sieweke MH,. Bissell MJ. The tumor-promoting effect of wounding: a possible role for TGF-beta-induced stromal alterations. Crit Rev Oncog 1994;5:297–311.

    PubMed  CAS  Google Scholar 

  41. Tagliabue E, Agresti R, Ghirelli C, Morelli D, Ménard S. Letter to the editor. The early relapse of premenopausal patients after surgery for node-positive breast carcinoma. Breast Cancer Res Treat 2001;70:155–6.

    Google Scholar 

  42. Tagliabue E, Agresti R, Carcangiu ML, Ghirelli C, Morelli D, Campiglio M, Martel M, Giovanazzi R, Greco M, Balsari A, Ménard S. Role of HER2 in wound-induced breast carcinoma proliferation. Lancet 2003;362:527–33.

    Article  PubMed  CAS  Google Scholar 

  43. Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, Barcos M, Cirrincione C, Edgerton S, Allred C, Norton L, Liu ET. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998;90:1346–60.

    Article  PubMed  CAS  Google Scholar 

  44. Paik SM, Bryant J, Park CH, Fisher B, Tan-Chiu E, Hyams D, Fisher ER, Lippman ME, Wickerham DL, Wolmark N. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998;90:1361–70.

    Article  PubMed  CAS  Google Scholar 

  45. Di Leo A, Gancberg D, Larsimont D, Tanner M, Jarvinen T, Rouas G, Dolci S, Leroy JY, Paesmans M, Isola J, Piccart MJ. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 2002;8:1107–16.

    PubMed  Google Scholar 

  46. Ozinsky A, Underhill DM, Fontenot JD, Hajjar AM, Smith KD, Wilson CB, Schroeder L, Aderem A. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci U S A 2000;97:13766–71.

    Article  PubMed  CAS  Google Scholar 

  47. Ménard S, Valagussa P, Pilotti S, Gianni L, Biganzoli E, Boracchi P, Tomasic G, Casalini P, Marubini E, Colnaghi MI, Cascinelli N, Bonadonna G. Response to Cyclophosphamide, Methotrexate, and Fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. J Clin Oncol 2001;19:329–35.

    PubMed  Google Scholar 

  48. Moliterni A, Ménard S, Valagussa P, Biganzoli E, Boracchi P, Balsari A, Casalini P, Tomasic G, Marubini E, Pilotti S, Bonadonna G. HER2 overexpression and doxorubicin in the adjuvant chemotherapy of resectable breast cancer. J Clin Oncol 2003;21:458–62.

    Article  PubMed  CAS  Google Scholar 

  49. Konecny GE, Thomssen C, Luck HJ, Untch M, Wang HJ, Kuhn W, Eidtmann H, du B A, Olbricht S, Steinfeld D, Mobus V, Von Minckwitz G, Dandekar S, Ramos L, Pauletti G, Pegram MD, Janicke F, Slamon DJ. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst 2004;96:1141–51.

    Article  PubMed  CAS  Google Scholar 

  50. Grunt TW, Saceda M, Martin MB, Lupu R, Dittrich E, Krupitza G, Harant H, Huber H, Dittrich C. Bidirectional interactions between the estrogen receptor and the c-erbB-2 signaling pathways: Heregulin inhibits estrogenic effects in breast cancer cells. Int J Cancer 1995;63:560–7.

    PubMed  CAS  Google Scholar 

  51. Elledge RM, Green S, Ciocca D, Pugh R, Allred DC, Clark GM, Hill J, Ravdin P, O’Sullivan J, Martino S, Osborne CK. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a southwest oncologty group study. Clin Cancer Res 1998;4:7–12.

    PubMed  CAS  Google Scholar 

  52. Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H, Slamon DJ. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 2003;95:142–53.

    PubMed  CAS  Google Scholar 

  53. Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451–67.

    Article  Google Scholar 

  54. Yang Z, Barnes CJ, Kumar R. Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells. Clin Cancer Res 2004;10:3621–8.

    Article  PubMed  CAS  Google Scholar 

  55. Johnston SR, Head J, Pancholi S, Detre S, Martin LA, Smith IE, Dowsett M. Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer. Clin Cancer Res 2003;9:524S–32S.

    PubMed  CAS  Google Scholar 

  56. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, Miller WR, Evans DB, Dugan M, Brady C, Quebe-Fehling E, Borgs M. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001;19:3808–16.

    PubMed  CAS  Google Scholar 

  57. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719–26.

    Article  PubMed  CAS  Google Scholar 

  58. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639–48.

    PubMed  CAS  Google Scholar 

  59. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783–92.

    Article  PubMed  CAS  Google Scholar 

  60. Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, Parker LM, Ellisen LW, Kuter I, Gadd MA, Christian RL, Kennedy PR, Borges VF, Bunnell CA, Younger J, Smith BL, Winer EP. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 2003;21:46–53.

    Article  PubMed  CAS  Google Scholar 

  61. Tedesco KL, Thor AD, Johnson DH, Shyr Y, Blum KA, Goldstein LJ, Gradishar WJ, Nicholson BP, Merkel DE, Murrey D, Edgerton S, Sledge GW, Jr. Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. J Clin Oncol 2004;22:1071–7.

    Article  PubMed  CAS  Google Scholar 

  62. Perez EA,. Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol 2004;22:322–9.

    Article  PubMed  CAS  Google Scholar 

  63. Garratt AN, Ozcelik C, Birchmeier C. ErbB2 pathways in heart and neural diseases. Trends Cardiovasc Med 2003;13:80–6.

    Article  PubMed  CAS  Google Scholar 

  64. Hieken TJ, Mehta RR, Shilkaitis A. HER-2/neu and p53 expression in breast cancer: valid prognostic markers when assessed by direct immunoassay, but not by immunohistochemistry. Proc Annu Meet Am Soc Clin Oncol 1996;15:113.

    Google Scholar 

  65. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989;9:1165–72.

    PubMed  CAS  Google Scholar 

  66. Sarup JC, Johnson RM, King KL, Fendly BM, Lipari MT, Napier MA, Ullrich A, Shepard HM. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Regul 1991;1:72–82.

    PubMed  CAS  Google Scholar 

  67. De Santes K, Slamon D, Anderson SK, Shepard M, Fendly B, Maneval D, Press O. Radiolabeled antibody targeting of the HER-2/neu oncoprotein. Cancer Res 1992;52:1916–23.

    PubMed  Google Scholar 

  68. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6:443–6.

    Article  PubMed  CAS  Google Scholar 

  69. Gennari R, Ménard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E, Castiglioni F, Villani L, Magalotti C, Gibelli N, Oliviero B, Ballardini B, Da Prada G, Zambelli A, Costa A. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004;10:5650–5.

    Article  PubMed  CAS  Google Scholar 

  70. Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P, Boulamatsis D. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer 2002;87:21–7.

    Article  PubMed  CAS  Google Scholar 

  71. Sfondrini L, Besusso D, Rumio C, Rodolfo M, Ménard S, Balsari A. Prevention of spontaneous mammary adenocarcinoma in HER-2/neu transgenic mice by foreign DNA. FASEB J 2002;16:1749–54.

    Article  PubMed  CAS  Google Scholar 

  72. Ménard S, Pupa SM, Casalini P, Rilke F, Colnaghi MI. Relationship of histological grade, c-erbB-2 expression and inflammatory infiltrate to prognosis in carcinoma of the breast-In reply. J Clin Oncol 1996;14:2407.

    Google Scholar 

  73. Rilke F, Colnaghi MI, Cascinelli N, Andreola S, Baldini MT, Bufalino R, Della Porta G, Ménard S, Pierotti MA, Testori A. Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 1991;49:44–9.

    PubMed  CAS  Google Scholar 

  74. Pupa SM, Bufalino R, Invernizzi AM, Andreola S, Rilke F, Lombardi L, Colnaghi MI, Ménard S. Macrophage infiltrate and prognosis in c-erbB-2-overexpressing breast carcinomas. J Clin Oncol 1996;14:85–94.

    PubMed  CAS  Google Scholar 

  75. Disis ML, Pupa SM, Gralow JR, Dittadi R, Ménard S, Cheever MA. High titer HER-2/neu protein specific antibody immunity can be detected in patients with early stage breast cancer. J Clin Oncol 1997;15:3363–7.

    PubMed  CAS  Google Scholar 

  76. Pupa SM, Ménard S, Andreola S, Colnaghi MI. Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients. Cancer Res 1993;53:5864–6.

    PubMed  CAS  Google Scholar 

  77. Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, Jeschke M, Lydon N, McGlynn E, Livingston RB, Moe R, Cheever MA. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 1994;54:16–20.

    PubMed  CAS  Google Scholar 

  78. Disis ML,. Cheever MA. HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv Cancer Res 1997;71:343–71.

    PubMed  CAS  Google Scholar 

  79. Foy TM, Fanger GR, Hand S, Gerard C, Bruck C, Cheever MA. Designing HER2 vaccines. Semin Oncol 2002;29:53–61.

    PubMed  CAS  Google Scholar 

  80. Kiessling R, Weil WZ, Herrmann F, Lindencrona JA, Choudhury A, Kono K, Seliger B. Cellular immunity to the Her-2/neu protooncogene. Adv Cancer Res 2002;85:101–44.

    Article  PubMed  CAS  Google Scholar 

  81. Piechocki MP, Ho YS, Pilon S, Wei WZ. Human ErbB-2 (Her-2) transgenic mice: a model system for testing Her-2 based vaccines. J Immunol 2003;171:5787–94.

    PubMed  CAS  Google Scholar 

  82. Rovero S, Amici A, Carlo ED, Bei R, Nanni P, Quaglino E, Porcedda P, Boggio K, Smorlesi A, Lollini PL, Landuzzi L, Colombo MP, Giovarelli M, Musiani P, Forni G. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 2000;165:5133–42.

    PubMed  CAS  Google Scholar 

  83. Di Carlo E, Rovero S, Boggio K, Quaglino E, Amici A, Smorlesi A, Forni G, Musiani P. Inhibition of mammary carcinogenesis by systemic interleukin 12 or p185neu DNA vaccination in Her-2/neu transgenic BALB/c mice. Clin Cancer Res 2001;7:830s–7s.

    PubMed  Google Scholar 

  84. Nanni P, Nicoletti G, De Giovanni C, Landuzzi L, Di Carlo E, Cavallo F, Pupa SM, Rossi I, Colombo MP, Ricci C, Astolfi A, Musiani P, Forni G, Lollini P-L. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J Exp Med 2001;194:1–12.

    Article  Google Scholar 

  85. Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 2001;107:477–84.

    Article  PubMed  CAS  Google Scholar 

  86. Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL, Schiffman K. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 2002;20:2624–32.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Molecular Targeting Unit, Department of Experimental Oncology, Istituto Nazionale Tumori, 20133, Milan, Italy

    S. Menard

Authors
  1. S. Menard
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag France, Paris

About this paper

Cite this paper

Menard, S. (2006). Breast cancer with HER 2 overexpressed. From laboratory to clinical practice. In: Cancer du sein. Springer, Paris. https://doi.org/10.1007/2-287-31109-2_11

Download citation

  • DOI: https://doi.org/10.1007/2-287-31109-2_11

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-25174-0

  • Online ISBN: 978-2-287-31109-3

Publish with us

Policies and ethics

Search

Navigation